Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cabaletta Bio Inc

CABA
Current price
16.06 USD +0.06 USD (+0.37%)
Last closed 16.02 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 686 447 424 USD
Yield for 12 month +223.14 %
Week
Month
Year
CABA
21.11.2021 - 28.11.2021

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Address: 2929 Arch Street, Philadelphia, PA, United States, 19104

Analytics

WallStreet Target Price

31.14 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -66 368 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -31.99 %
PEG Ratio
Return On Equity TTM -50.63 %
Wall Street Target Price 31.14 USD
Revenue TTM
Book Value 3.86 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -1.7 USD
Diluted Eps TTM -1.7 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CABA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -7.9175
Price Book MRQ 4.2604

Financials CABA

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CABA

For 52 weeks

4.43 USD 19.34 USD
50 Day MA 15.5 USD
Shares Short Prior Month 6 283 668
200 Day MA 12.34 USD
Short Ratio 8.42
Shares Short 5 055 971
Short Percent 13.37 %